5,6-二甲氧基茚烷-1-乙酸 | 62956-65-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 5,6-二甲氧基茚烷-1-乙酸
• 英文名称: 5,6-dimethoxyindan-1-acetic acid
• 英文别名: 2-(5,6-dimethoxyindan-1-yl)-acetic acid；2-(5,6-dimethoxy-2,3-dihydro-1H-inden-1-yl)acetic acid
• CAS: 62956-65-4
• 化学式: C₁₃H₁₆O₄
• 分子量: 236.268
• InChiKey: QDTUIHOOSMFIDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  5,6-二甲氧基茚烷-1-乙酸 在 硫酸 、 一水合肼 作用下， 以 丙醇 为溶剂， 反应 6.0h， 生成 5,6-dimethoxyindan-1-acetylhydrazide
  参考文献：
  名称：

  Pramanik, S. S.; Mukherjee, A., Journal of the Indian Chemical Society, 1998, vol. 75, # 1, p. 53 - 54

  摘要：

  DOI：
• 作为产物：
  描述：

  diethyl 2,4-diacetyl-3-(3,4-dimethoxyphenyl)pentanedioate 在 盐酸 、 氢氧化钾 、 amalgamated zinc 、 PPA 作用下， 以 乙醇 、 苯 为溶剂， 生成 5,6-二甲氧基茚烷-1-乙酸
  参考文献：
  名称：

  Pramanik; Mukherjee, Journal of the Indian Chemical Society, 1997, vol. 74, # 9, p. 734 - 735

  摘要：

  DOI：

文献信息

• Synthesis and biological evaluation of amide derivatives of (5,6-dimethoxy-2,3-dihydro-1H-inden-1-yl)acetic acid as anti-inflammatory agents with reduced gastrointestinal ulcerogenecity
  作者：Meenakshi Sharma、S.M. Ray

  DOI：10.1016/j.ejmech.2007.08.008

  日期：2008.10

  A variety of amide derivatives of (5,6-dimethoxy-2,3-dihydro-1H-inden-1-yl)acetic acid were synthesized and screened for their analgesic and anti-inflammatory activities. The compounds were found to have longer activity profile exceeding that of indomethacin in carrageenan-induced rat paw edema model. Few selected compounds were also screened for their antipyretic, anti-arthritic and ulcerogenecity

  合成了多种（5,6-二甲氧基-2,3-二氢-1H-茚满-1-基）乙酸的酰胺衍生物，并筛选了其镇痛和抗炎活性。在角叉菜胶诱导的大鼠爪水肿模型中，发现该化合物具有比消炎痛更长的活性谱。很少筛选出具有退烧，抗关节炎和致溃疡性的化合物。从这些研究可以得出结论，这些化合物尽管具有显着的解热活性，但并未通过抑制TNF-α发挥作用。在佐剂诱导的关节炎测定中，测试化合物未能阻止继发性炎症的发展。但是，这些化合物在100 mg / kg po的测试剂量水平下未显示溃疡形成
• Aromatic amide derivatives of 5,6-dimethoxy-2,3-dihydro-1H-inden(-1-yl)acetic acid as anti-inflammatory agents free of ulcerogenic liability
  作者：Meenakshi Sharma、S.M. Ray

  DOI：10.1016/j.bmcl.2007.10.037

  日期：2007.12

  Amide derivatives of 5,6-dimethoxy-2,3-dihydro-1H-inden(-1-yl)acetic acid were synthesized and evaluated for their anti-inflammatory and analgesic activity. Few selected compounds were also screened for their antipyretic, anti-arthritic, and ulcerogenic potential. Most of the compounds exhibited good activity profile and were free of gastrointestinal toxicity of common NSAIDs. However these compounds

  合成了5,6-二甲氧基-2,3-二氢-1H-茚满（-1-基）乙酸的酰胺衍生物，并对其抗炎和镇痛活性进行了评估。很少筛选出具有退烧，抗关节炎和致溃疡潜力的化合物。大多数化合物表现出良好的活性，并且没有常见的非甾体抗炎药的胃肠道毒性。然而，这些化合物不能减少佐剂诱导的关节炎的继发性病变，也不能抑制脂多糖诱导的发热中的TNF-α。
• Substituted hydroxyureas
  申请人：Ortho Pharmaceutical Corporation

  公开号：US05066658A1

  公开（公告）日：1991-11-19

  The present invention relates to substituted hydroxyureas. These compounds inhibit the enzyme 5-lipoxygenase. In addition, certain of the compounds also inhibit the enzyme-cyclooxygenase. The compounds are useful for treating asthma, allergies, arthritis, posoriasis, ischemia, dermatitis, inflammation and/or broncho-constriction and/or inflammatory diseases of the eye.

  本发明涉及取代脲醇。这些化合物抑制5-脂氧合酶酶。此外，其中某些化合物还抑制酶-环氧合酶。这些化合物用于治疗哮喘、过敏、关节炎、银屑病、缺血、皮炎、炎症和/或支气管收缩和/或眼部炎症性疾病。
• Characterization of Potent and Selective Antagonists at Postsynaptic 5-HT1A Receptors in a Series of N4-Substituted Arylpiperazines
  作者：Jean-Louis Peglion、Herve Canton、Karin Bervoets、Valerie Audinot、Mauricette Brocco、Alain Gobert、Sylvie Le Marouille-Girardon、Mark J. Millan

  DOI：10.1021/jm00020a020

  日期：1995.9

  Benzocycloalkyl and benzocycloalkenyl moities linked, directly or via an alkyl chain, to oxygen-bearing heteroarylpiperazines were synthesized, in an attempt to obtain potent and selective antagonists at postsynaptic 5-HT1A receptors. From the numerous arylpiperazines described in the literature, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)pipe (3a) was chosen as a model of an arylpiperazine in view of its selectivity for 5-HT1A receptors versus alpha(1)-, alpha(2)-, and beta-adrenergic receptors, as well as dopamine D-1 and D-2 receptors. Two other closely-related arylpiperazines, 1-(1,5-benzodioxepin-6-yl)piperazine (3b) and 1-(benzofuran-7-yl)piperazine (3c), were also examined in this study. Al compounds showed high affinity at 5-HT1A sites (8.10 less than or equal to pK(i)s less than or equal to 9.35), and the majority behaved as antagonists in vivo in blocking the hypothermia induced by the 5-HT1A agonist 8-OH-DPAT in the absence of a marked effect alone at equivalent doses. An in vivo evaluation of dopamine D-2 receptor antagonist properties revealed that the majority of compounds was devoid of activity at this site, in marked contrast to BMY 7378 which displayed virtually no selectivity for 5-HT1A versus dopamine D-2 receptors. Moreover, six compounds of the present series, 8, 10, 11, 14, 25, and, 37, showed > 10-fold selectivity in vitro for 5-HT1A versus alpha(1)-adrenergic receptors. Compound 14 displayed an optimal compromise between potency (pK(i) = 8.75), marked antagonist activity, and selectivity toward alpha(1)-adrenergic (81-fold) and dopamine D-2 (195-fold) receptors. These characteristics clearly distinguish 14 from previously-reported ligands such as the postsynaptic 5-HT1A antagonist BMY 7378 and the weak partial agonist NAN 190 which, in contrast to the compounds of this series, belong to the well-exemplified class of imido derivatives of (o-methoxyphenyl)piperazines. The availability of 14 (S 15535) should facilitate the further elucidation of the functional role and potential therapeutic significance of 5-HT1A receptors.
• Mukhopadhyay; Roy; Lahiri, Journal of the Indian Chemical Society, 1985, vol. 62, # 9, p. 690 - 692
  作者：Mukhopadhyay、Roy、Lahiri

  DOI：——

  日期：——